AMGEN TO WEBCAST INVESTOR CALL AT ESMO 2022
Amgen (NASDAQ:AMGN) will host a webcast for the investment community on Sept. 12, 2022, at 1:30 p.m. ET, during the European Society for Medical Oncology Annual Congress (ESMO). Dr. David M. Reese and Amgen's clinical team will discuss findings from the LUMAKRAS® (sotorasib) CodeBreaK 200 study in non-small cell lung cancer, as well as the Phase 1b expansion of LUMAKRAS with Vectibix® (panitumumab) in colorectal cancer. The webcast will be available to the media, investors, and the public, and archived for 90 days on Amgen's website.
- None.
- None.
THOUSAND OAKS, Calif., Sept. 7, 2022 /PRNewswire/ -- Amgen (NASDAQ:AMGN) will host a webcast call for the investment community in conjunction with the European Society for Medical Oncology Annual Congress (ESMO) at 1:30 p.m. ET on Monday, Sept. 12, 2022. David M. Reese, M.D., executive vice president of Research and Development at Amgen, along with members of Amgen's clinical development team, will discuss the data being presented from the LUMAKRAS® (sotorasib) CodeBreaK 200 confirmatory Phase 3 study in non-small cell lung cancer and data from the full Phase 1b expansion cohort of LUMAKRAS in combination with Vectibix® (panitumumab) in colorectal cancer. The webcast will be broadcast over the internet simultaneously and will be available to members of the news media, investors and the general public.
The webcast, as with other selected presentations regarding developments in Amgen's business given by management at certain investor and medical conferences, can be found on Amgen's website, www.amgen.com, under Investors. Information regarding presentation times, webcast availability and webcast links are noted on Amgen's Investor Relations Events Calendar. The webcast will be archived and available for replay for at least 90 days after the event.
About Amgen
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
Amgen is one of the 30 companies that comprise the Dow Jones Industrial Average and is also part of the Nasdaq-100 index. In 2021, Amgen was named one of the 25 World's Best Workplaces™ by Fortune and Great Place to Work™ and one of the 100 most sustainable companies in the world by Barron's.
For more information, visit www.amgen.com and follow us on www.twitter.com/amgen.
CONTACT: Amgen, Thousand Oaks
Jessica Akopyan, 805-447-0974 (media)
Megan Fox, 805-447-1423 (media)
Arvind Sood, 805-447-1060 (investors)
View original content to download multimedia:https://www.prnewswire.com/news-releases/amgen-to-webcast-investor-call-at-esmo-2022-301619654.html
SOURCE Amgen
FAQ
When is Amgen's investor call at ESMO 2022?
Who will present at the Amgen webcast during ESMO 2022?
What studies will be discussed in Amgen's ESMO 2022 webcast?
Where can I watch the Amgen ESMO 2022 webcast?
What is LUMAKRAS and its significance?
